Clinical Trial: A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07727538) titled 'A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants' on July 10.

Brief Summary: The primary purpose of the study is to evaluate the efficacy of olezarsen administered by subcutaneous injection to pediatric participants with FCS.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Familial Chylomicronemia Syndrome

Intervention: DRUG: Olezarsen

Olezarsen will be administered by subcutaneous injection.

Recruitment Status: RECRUITING

Sponsor: Ionis Pharmaceuticals, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....